Navigation Links
Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
Date:4/16/2008

-060 treatment was well-tolerated with no clinically meaningful infusion reactions. The most frequently reported drug-related adverse events were fatigue and pyrexia considered to be mild to moderate in severity.

About Anti-CD30 Antibody Therapy

MDX-060 is a fully human antibody that targets CD30, a marker found on activated lymphocytes that is present on malignant cells of Hodgkin's disease (HD) as well as other CD30-expressing cancers. Medarex is currently conducting an ongoing Phase 2 proof-of-concept trial of MDX-060 in combination with gemcitabine for HD. Medarex is also developing MDX-1401, a second-generation non-fucosylated version of the MDX-060 parental antibody, that is enhanced for greater antibody-dependent cellular cytotoxicity and is being explored in a multi-dose, dose-escalation Phase 1 clinical trial for HD.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... MA (PRWEB) July 29, 2014 The ... Library of Congress was recently awarded to Juliana Hillis ... Stoneham, MA, for their project, “From an Egg, Everything: ... among 3,000 final entries for the National History Day ... than 300 historians and educators in Washington, D.C. , ...
(Date:7/29/2014)... 29, 2014 EXpressLO LLC, expert provider ... specimen preparation solutions, has been granted patent number 8,789,826 ... manipulation methods incorporating a unique specimen carrier support grid ... the second company patent for EXpressLO LLC awarded to ... , These complementary patents extend EXpressLO’s portfolio of intellectual ...
(Date:7/28/2014)... DIEGO , July 28, 2014 ... cultivation technologies, today announced the appointment of biotechnology veteran ... of the board of directors. Levine replaces Cynthia ,CJ, ... immediately. She will remain chairman of the company,s board ... on Sapphire Energy,s mission to deliver commercial scale algae-based ...
(Date:7/28/2014)... July 28, 2014 According to ... Market Research "Regenerative Medicine (Bone and Joint) Market ... Tissue Engineering; By Applications - Bone Graft Substitutes, ... - Global Industry Analysis, Size, Share, Growth, Trends ... medicine (bone and joint) market was valued at ...
Breaking Biology Technology:In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3EXpressLO LLC Granted Second U.S. Patent for Innovative Specimen Preparation Methods 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4
... for Presentation at ASCO, SOUTH SAN FRANCISCO, Calif., May ... it will hold an investor and,analyst briefing in conjunction with ... (ASCO) from 6:00 p.m. to 8:00 p.m. CT,on Monday, June ... PhD, President and Chief Executive Officer -- Michael M. ...
... Mass., May 21 Interleukin Genetics,Inc. (Amex: ... into law of the,Genetic Information Nondiscrimination Act (GINA). ... April 25, 2008, and signed into law by,President ... intended to ensure that individuals are protected,from genetic ...
... Germany, Mai 21, 2008 / b3c newswire ... both leading companies in biopharmaceutical development and ... The cooperation will enable Rentschler Biotechnologie’s clients ... mammalian biopharmaceutical production facilities in Biberach, Germany ...
Cached Biology Technology:Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing 2Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing 3Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing 4Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA) 2Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA) 3Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim 2Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim 3
(Date:7/27/2014)... has revealed that nicotine and cotinine, a metabolite of ... certain carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or ... and ultimately ends up in the tobacco smoke. Once ... where it is activated by a variety of enzymes ... revealed that nicotine can partially interfere with the activation ...
(Date:7/27/2014)... can evade treatment by acquiring mutations in the genes ... were once thought to be the only way for ... shown that microorganisms can use a temporary silencing of ... the benefits of drug resistance without the commitment. , ... called Mucor circinelloides, it is likely to be employed ...
(Date:7/27/2014)... patients, scientists have identified more than two dozen ... six that had not been previously reported. The ... partially funded by the National Institutes of Health ... laboratories. , "Unraveling the genetic underpinnings of Parkinson,s ... in this complex disease, and hopefully, may one ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3NIH scientists find 6 new genetic risk factors for Parkinson's 2
... ice-free summers with intermittent winter sea ice in the Arctic ... conditions - gives a glimpse of how the Arctic is ... past environmental change in the Arctic should help predict its ... 65 million years ago leading up to the extinction of ...
... PHILADELPHIA Researchers from the Centers for Disease Control ... ovarian cancer is influenced by age of menarche and ... suggests that hormonal activity over the course of a ... cancer diagnosis. Results of this study are published in ...
... Environmental Health Perspectives (EHP) co-authored by ... Project on Emerging Nanotechnologies (PEN), focuses on the ... provides an overview of current practices; research findings; ... and possible future directions for nanoremediation. The authors ...
Cached Biology News:Arctic climate under greenhouse conditions in the Late Cretaceous 2Arctic climate under greenhouse conditions in the Late Cretaceous 32 reproductive factors are important predictors of death from ovarian cancer 22 reproductive factors are important predictors of death from ovarian cancer 3Contaminated site remediation: Are nanomaterials the answer? 2